Summary
SUMMARY Heart failure is a leading cause of death worldwide, and the leading cause of hospital admissions in patients over 65 in the US. The role of metabolism in cardiac pathology has long been of interest, but no therapies that target cardiac metabolism are known. Recently, Na+/glucose transporter 2 inhibitors (SGLT2i), originally designed as therapies for diabetes, have taken HF management by storm, demonstrating 20-30% reductions in heart failure hospitalizations in large phase III trials, even in patients without diabetes. How SGLT2i confer these benefits remains a mystery. In extensive p
